Physician profile
Erik C Walker
NPI 1710977954
$9,958.96
in general payments reported to CMS, 2019-2025
53 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,878 · 2020: $1,621 · 2021: $2,469 · 2022: $2,078 · 2023: $1,871 · 2024: $40.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,911.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.96 | 2019-2023 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $1,063.42 | 2019-2023 | Prolia |
| Novo Nordisk INC | $882.45 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceuticals, INC. | $704.05 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $693.83 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.64 | 2019-2023 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $486.86 | 2019-2022 | |
| Lilly USA, LLC | $431.46 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $428.56 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $423.40 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $389.95 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $385.56 | 2022 | |
| Amarin Pharma, INC. | $325.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $202.04 | 2019-2023 | |
| Abbott Laboratories | $169.52 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.